Archive for the ‘Treatment’ Category

First Case Report of Pancreatitis in Lyme Disease

https://researchopenworld.com/first-case-report-of-pancreatitis-in-lyme-disease/

First Case Report of Pancreatitis in Lyme Disease

Publication history

Received: November 14, 2019
Accepted: November 21, 2019
Published: November 25, 2019

Citation

A Baisse, S Parreau, A Abdeh, N Pichon (2019) First Case Report of Pancreatitis in Lyme disease. Internal Med Res Open J Volume 4 (2): 1–2. DOI: 10.31038/IMROJ.2019423

Short Abstract

We report a case of Lyme disease, revealed by pancreatic damage in a 49-year-old man without any medical history. The Lyme disease was revealed by repeated abdominal pain for 4 weeks, a skin lesion of quadricipital region, biological and radiological results showing pancreatic abnormalities.

Case Report

A 49-year-old man, non-alcoholic forest worker, with no past medical history, consulted to the Emergency Department for fever and persistent abdominal pain for a week. The biological results including, C – reactive protein (CRP), lipase, hepatic assessment were normal as well as contrast-enhanced abdominal Computed Tomography (CT). On the day after, the evolution was favorable under symptomatic treatment including nefopam and paracetamol and the patient was discharged from the hospital. One week later, the patient was admitted to the Emergency Department with an identical symptomatology. A posterior quadricipital peeling skin lesion, appeared two weeks earlier according to the patient, was observed (Figure 1a.) A gastroscopy, a colonoscopy, other abdominal CT and biological tests were performed. An inflammation biomarker elevation was observed (CRP: 180 mg/L and hyperleukocytosis: 13.3 G/L) without other biological abnormalities (lipase: 48 UI/L, ALAT: 48 UI/L). The endoscopic examinations and abdominal CT were normal. The patient was discharged from the hospital without any treatment. Half a month later, the patient was admitted to the Emergency Department for the third time and recurrence of the abdominal pain. The clinical examination found a hemodynamic stability, an abdominal pain of the left hypochondrium associated with a cutaneous ulcerative and non-progressive skin lesion in the same region as previously mentioned (Figure 1b.). The biological assessment found a very mild inflammatory syndrome (CRP 86 mg/L, Procalcitonin < 0.2 ng/mL, leukocytes 9.5 G/L), a high lipase level at 1714 IU/L without hepatocellular abnormalities. The third abdominal CT revealed an aspect of pancreatic necrosis with a pseudocyst (6 cm) at the tail of the pancreas, in contact with the splenic hile and the posterior wall of the stomach (Figure 1c.). The patient was hospitalized in Intensive Care Department with the diagnosis of pancreatitis.

On admission, the work-ups looking for the usual causes of pancreatitis (alcohol, gallstones, medications induced, hypercalcemia, traumatic, chemical exposures, hereditary diseases, infections) were negative. Regarding the skin patient’s lesion and anamnesis, the diagnosis of Lyme disease was evoked. His Lyme serology was strongly IgM positive and confirmed by Western Blot. He was treated with ceftriaxone associated with effective analgesic therapy. The clinical and biological course was uneventful and the patient was discharged from the hospital after 3 weeks. The relationship between Lyme disease and acute pancreatitis was strongly suspected.

Discussion

Lyme disease is an endemic zoonosis, transmitted to humans by a tick bite causing a multisystemic impairment due to a Gram-negative bacillus, Borrellia burgdorferi [1]. The disease schematically includes two phases and a polymorphism in clinical manifestations: a primary phase with chronical migrans erythema and articular signs (80% of cases), a secondary phase of heterogeneous and lymphatic dissemination, inaugurated by flu-like symptoms and associating neurological, cardiac or articular signs that could become chronic [2]. Each of these attacks could be inaugural or/and isolated [3]. Concerning the anamnesis, only 30% of patients remember a tick bite [4].

The heterogeneity of presentation in Lyme disease includes the serodiagnosis as a central investigation for confirmation [5]. Hepatic impairment due to Lyme disease, including hepatitis and hepatomegaly, is inconsistent, commonly found in early stage but often asymptomatic and with plasmatic manifestations [6]. A moderate hypertransaminasemia (2 to 3 N) could be noted, predominating on the ALAT. This hepatic biologic involvement is present in 27 to 66% of cases [7]. This can be explained by a systemic, lymphatic migration of the incriminated bacteria and a secondary hepatic sequestration [8]. To our knowledge, this physiopathological evolution to explain liver disorders has never been described for pancreas but is probably similar.

Regarding the treatment of Lyme disease, the cycline are recommended for the uncomplicated forms. An antibiotic treatment with cephalosporins could be considered for cardiac, neurological or complicated cases [2]. The evolution is favorable in 85% of patients, including hepatic acute injuries [9].

In our case, the skin lesion associated with a supposed tick bite, the anamnesis, the absence of other cause of pancreatitis, the favorable evolution under antibiotic treatment and especially the strong positivity of the serology are in favor of a Borrelia burgdoferi infection.

Conclusion

The authors report the first case of pancreatitis revealing a Lyme disease. Clinical, biological and evolutionary findings support the responsibility of Lyme disease in the pathogenesis of our pancreatitis case.  (See link for article and pictures)

_________________

**Comment**

How many patients have had this or similar issues but didn’t have the rash, had negative serology and didn’t fit the other arbitrary standards that mainstream medicine has imposed that thousands of other patients don’t fit?  God only knows.

Category:

Lyme, research, Testing, Treatment

Research Suggests Cancer Medication Could Help Fight Lyme Disease

https://www.wamc.org/news/2023-08-08/research-suggests-cancer-medication-could-help-fight-lyme-disease

Research suggests cancer medication could help fight Lyme Disease

WAMC Northeast Public Radio | By Jim Levulis
Published August 8, 2023
U.S. Dept. Of Agriculture

Research out of UMass Amherst suggests medication used to stop the spread of cancer may help fight tick-borne illnesses such as Lyme Disease. WAMC’s Jim Levulis spoke with Stephen Rich, the executive director of the New England Regional Center of Vector-borne Diseases, about the study and how it relates to existing Lyme treatments.

Rich: Generally that’s antibiotic treatments, most often doxycycline. A reasonable course of doxycycline takes care of most early detected Lyme disease cases. There other antibiotics where doxycycline is contraindicated, there are other antibiotics that work as well. Things like amoxicillin, but basically antibiotics.

(See link for article and interview)

_________________

SUMMARY:

  • Lyme spirochetes have a dependency upon a particular pathway called glycolysis which is dependent upon lactate dehydrogenase or LDH.
  • Certain cancer cells are similarly constrained in their metabolic profiles.
  • Inhibitors of the LDH molecule have been used to treat cancerous tumors.
  • The inhibitors, when tested in the test tube against Lyme spirochetes didn’t eliminate the borrelia, but they stopped it from growing (bacteriostatic).
  • They are now going to test this in lab animals and then companion animals or people.
  • Despite it being a wet, warm July in Massachusetts, there were lots of ticks at work.

For more on Lyme treatments utilized by experienced Lyme literate doctors (LLMDs) go here.

I must add that this proves ticks are ecoadaptive and tick and disease proliferation has nothing to do with the weather or supposed ‘climate change,’ which is simply a propaganda narrative touted by climate scientists who are on a “gravy train” to secure funding via government grants.

Expert after expert has stated “there is no climate emergency.”

Further, ‘the powers that be’ are using the climate agenda to desperately push a much bigger diabolical plan:  UN’s  Our Common Agenda platform, the WHO’s Pandemic Treaty, and the WEF’s depopulation, massive surveillance, and censorship designs which will give unelected officials unlimited power with ZERO oversight.

Do not fall for the unscientific clap-trap of ‘climate change.’  It’s part of an evil dystopian plan.

Category:

Cancer, Lyme, research, Treatment

Kris Kristofferson “…As Sharp As He’s Been in the Past 20 Years Because of His Treatments”

https://www.survivornet.com/articles/country-singer-songwriter-kris-kristofferson-lyme-disease-alzeimers/

Country Singer-Songwriter Kris Kristofferson, 87, Had Symptoms Misdiagnosed As Alzheimer’s But It Turned Out To Be Lyme Disease

Danielle Cinone
8/2/23
Excerpts:
  • Singer-songwriter Kris Kristofferson, known for writing the hit song “Me and Bobby McGee,” had been falsely diagnosed with Alzheimer’s. Instead, the country star was actually suffering from a tick-borne illness known as lyme disease.
  • “But we suspect he’s been infected with Lyme anywhere from fourteen to thirty years because he used to have these chronic muscle spasms, which is a common symptom. We were in LA at the time, in Malibu, and I just don’t think doctors were looking for it or aware of it there then. But now we know it’s everywhere. There are signs on my local playground that say beware of ticks.”
  • Kristofferson’s wife added, “He had painful knees and annual knee shots, a pacemaker for arrhythmias– which we now know could be from Lyme- so much Advil for headaches that he got anemic. After a year of iron supplements and seeing a hematologist, he just wasn’t healthy-looking so I took him to an integrative doctor, Mark Filidei, at Whitaker Wellness Institute.

    “Upon examining Kris and watching the muscles in his forearms constantly twitching, he announced, ‘He’s got Lyme disease,’ and ordered a blood test. The first test from LabCorp came back suspicious, the second test by IGeneX was positive. This was in February 2016.”

(See link for article)

_________________

**Comment**

The article then moves onto cancer because the website focuses on minsdiagnosises.  The advice to those diagnosed with cancer:  be proactive, seek out multiple opinions, and “be a little pushy,” also holds true for Lyme/MSIDS due to the severe polarization within the medical community.  Your best bet for achieving wellness is going to come from a Lyme literate doctor (LLMD).

Lastly, there has been research done on the connection between Lyme and cancer as well as in other coinfections.

For more:

Category:

Alzheimer's, Lyme, Treatment

ACTION ALERT: FDA Trying to Ban CBD

https://www.paintreatmentdirectory.com/posts/the-fda-is-trying-to-ban-cbd-supplements

The FDA is Trying to Ban CBD Supplements

The FDA is Trying to Ban CBD Supplements

By: ANH-USA

Editor’s note: The following article and call to action about the FDA’s efforts to ban CBD supplements is being reprinted from the Alliance for Natural Health website. This is not the first time the FDA has tried banning natural treatments relied on by millions of Americans, but part of a long and corrupt history. The FDA has also been trying for several years to ban kratom, an herb being successfully used by millions of Americans to treat pain, opioid addiction and withdrawal, anxiety and more. Recently, the FDA has also taken action against homeopathy, a safe, natural system of medicine used worldwide since its development in 1810. The FDA has been trying to get stronger regulatory authority to take vitamins and other supplements off the market. It seems the FDA is leaving no stone unturned in its efforts to protect the profits of the pharmaceutical industry instead of protecting the health of the public.

The FDA Misleads on CBD Safety

…providing further evidence that the agency is trying to engineer a ban on affordable CBD to protect drug industry profits. Action Alert!

As the evidence of CBD’s myriad health benefits continues to pile up, it increasingly looks to us like the FDA is preparing to issue a ban on CBD supplements. We must support bills in Congress that take the issue out of the FDA’s hands by allowing the sale of CBD in supplement form.

Lawmakers do appear to be taking this issue seriously. In addition to the bill introduced by Representative Morgan Griffith (R-VA), another similar bill has just been introduced by Senators Ron Wyden (D-OR), Rand Paul (R-KY), Jeff Merkley (D-OR), and Representative Earl Blumenauer (D-OR) to allow the sale of CBD in supplements. Additionally, Congress is holding a hearing on July 27 during which members will formally scrutinize the impact of the FDA’s failure to develop a regulatory pathway for the sale of CBD in supplements and food. Let’s show the FDA the scale of our opposition to its unjustified plan and demonstrate the huge level of grassroots support for CBD supplements ahead of the hearing.

We want to make it crystal clear what we face if we don’t stop the FDA in its tracks. CBD, or cannabidiol, is one of over 100 natural compounds called cannabinoids found in a wide range of plants, most notably the hemp plant. The cells of our bodies are laced with cannabinoid receptors that form part of the endocannabinoid system that is essential to life and to robust health. We produce cannabinoids internally (endocannabinoids) and we also consume them in some foods (exocannabinoids). Most of these cannabinoids, including CBD, are not psychoactive – THC being an exception – but they all offer profound benefits. CBD is one of the most well researched non-psychoactive cannabinoids and it has an incredible array of health benefits, with evidence showing that has profound anti-inflammatory and immune modulating effects and can help with pain, anxiety, depression, certain cancers, and even heart health.

Let that sink in for a moment. The opioid epidemic is killing an astonishing number of Americans every year; rates of anxiety and depression are reaching new highs, particularly among young people; heart disease is the leading cause of death for adults in the US. CBD has been found to help with all of these conditions, but instead of working to make this compound more widely available as a supplement, which is the way it should be sold according to the Dietary Supplement and Health Education Act of 1994 (DSHEA), the FDA wants to stop all supplement sales of CBD. The FDA’s justification is the protection of the profits of one pharmaceutical company that has a CBD drug that will cost patients a stunning $32,500 per year. It will also mean citizens who have been benefiting from low-cost health support from CBD supplements since they became widely available a few years ago will have no further access to the supplements they have relied on. There is something deeply wrong with this picture.

How did we get here? For starters, the FDA says that CBD can’t be a supplement because it has approved a drug version of CBD called Epidiolex that is used to treat two rare forms of epileptic seizure, Lennox-Gastaut syndrome (LGS) or Dravet syndrome, in children over 2 years. This ability for FDA to rule in favor of drug companies has to do with the FDA back-channel that we’ve written about many times before. In short, if a substance is studied as a drug (i.e. a drug company has made an Investigational New Drug application) before there is evidence it was sold as a supplement (i.e. evidenced by a supplement company’s New Dietary Ingredient notification), then the drug company can ask the FDA to ban the supplement form of that compound.

Yet, as pressure mounts from Congress and a variety of stakeholders to make CBD more widely available, the FDA has been reviewing scientific information on CBD. Earlier this year, the agency released a statement explaining that the “existing regulatory framework” for foods and supplements is not appropriate for CBD and that a new regulatory pathway is needed.

One of the main issues raised by the FDA is that of safety. The agency claims that CBD presents various safety concerns, specifically the potential for harm to the liver and the reproductive system and concerns for vulnerable populations such as children and pregnant women.

These views are articulated in a review article authored in part by FDA staff. To support the assertion that CBD can pose threats to the male reproductive system, the authors cite a 1981 animal study in which monkeys were administered 30, 100, or 300 milligrams per kilogram of body weight per day (mg per kg bw/day) of CBD orally. But consider that 300 mg per kg bw/day for a human weighing 154 pounds would be 21,000 mg, or 21g, of CBD—far, far more than anyone would ever take as a supplement!

This is emblematic of a larger problem we’ve discussed before: the deeply flawed risk assessment models used by federal bureaucrats to prevent us from utilizing natural medicines to stay healthy. These types of models have been used by European regulators to set absurd limits on supplement dosages (known as tolerable upper limits, or ULs). ANH’s founder and Executive and Scientific Director, Robert Verkerk, PhD, has published several papers critiquing this approach that was originally developed by the Institute of Medicine (now the National Academy of Medicine), pointing to a fundamental flaw: in trying to restrict vitamin or other micronutrient dosages in this way, regulators completely ignore the fact that risks vary greatly depending on the form and dose of a nutrient used, and for most populations you’ll find overlap in the doses that cause health benefits for the majority and risks for a few. So if you then create a law that aims to eliminate a potential risk for everyone, you actually deprive the vast majority access to the micronutrient and all the benefits it offers.

Bringing it back to CBD: the fact that the FDA is, in part, using a decades-old animal study in which an absurdly high CBD dose was used to demonstrate that CBD has safety concerns once again demonstrates that the federal approach to assessing risk and benefit is fundamentally broken. It’s based on a defunct toxicological model that should have no place in modern day food or supplement law-making. The agency is also not giving proper weight to the incredibly favorable safety record of CBD used as a supplement or the multitude of benefits we can get from using CBD as a supplement. Instead, the FDA has chosen to focus on old evidence of harm that was only found when absurdly high doses were taken experimentally. To us, it seems like the agency is simply grasping at any information it can to demonstrate harm so it can justify its proposed ban on CBD supplements. The driver? Nothing less than preventing competition for the pharmaceutical drug version of CBD, given its the drug companies that are the FDA’s principal paymasters.

And, indeed, the FDA’s view on CBD’s safety is not supported by experts in the industry and elsewhere. A 2020 meta-analysis looked at human trials to assess CBD efficacy and safety. The authors concluded that most studies reported no adverse events with acute administration of CBD and mild to moderate effects with chronic administration, with the most common side effects being tiredness, diarrhea and changes of appetite/weight. Again, these side effects must be weighed against the benefits of CBD use for combatting opioid misuse, heart disease, anxiety, and depression. Harvard Health Publishing, the publication of the Harvard Medical School, states simply that, for adults, “CBD appears to be very safe.”

We cannot allow the FDA to cater to the drug industry at the expense of public health.

Action Alert! Write to Congress in support of bills that allow the legal sale of CBD in supplements. Please send your message immediately.

The FDA has said that they will not be allowing CBD to be in food or supplements, explaining that the “existing regulatory framework” for foods and supplements are not appropriate for CBD. The agency denied three Citizens Petitions requesting the agency issue a regulation that would allow CBD to be sold as a supplement. Clearly the FDA is more interested in protecting Big Pharma profits than with promoting consumer access to a product that can benefit their health. We need Congress to take the issue out of the FDA’s hands to create a legal pathway for CBD supplements.

Write to Congress and tell them to support the Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2023 and the Hemp Access and Consumer Safety Act to protect access to CBD supplements.

Sign the Petition Here

_________________

**Comment**

The FDA wants patients between a rock and a hard place.  On one hand they state extended antibiotics are not to be used for Lyme/MSIDS because they are unsafe, and then they also want to remove important supplements that help us, but when the agency is alerted to the fact doctors have never witnessed so many “vaccine”-related injuries and VAERS reports are higher than any other vaccine in its history, after the mRNA gene therapy injections……crickets.

Something doesn’t smell right.

If the FDA had their way we’d just all die already.

For more:

The FDA has a long & sordid history of attempting to ban anything it views as competition to its lucrative drugs & vaccines due to its vested interests with Big Pharma.

Category:

Activism, Herbs, Inflammation, Pain Management, Sleep, Supplements, Treatment

The Lyme Puzzle: Interview With Professor Nicole Baumgarth

https://podcast.tickbootcamp.com/episode/8bc4afa1/the-lyme-puzzle-an-interview-with-professor-nicole-baumgarth

Episode 364: The Lyme Puzzle – an interview with Professor Nicole Baumgarth

July, 2023

Introduction

  • In this episode of Tick Boot Camp, our hosts Matt Sabatello and Rich Johannesen had the opportunity to talk with the remarkable Professor Nicole Baumgarth, director of the Lyme and Tick-Borne Diseases Institute at Johns Hopkins University. Baumgarth brings a unique interdisciplinary background in veterinary medicine, immunology, microbiology, and pathology offering fresh insights into the complex world of Lyme disease and tick-borne illnesses.

Lyme Disease Research

  • Baumgarth and her team are investigating why we don’t mount an effective adaptive immune response to Lyme as we do with influenza (the flu).
  • She reveals their interesting finding about how Borrelia may alter the host’s gut microbiome to enhance its survival.
  • Baumgarth and her team are currently investigating why macrophages, immune cells that gobble up pathogens outside of our cells, don’t eat up Lyme bacteria as they do with other bacteria and viruses.
  • They are also investigating the impact Lyme has on obliterating our lymph nodes, which are critical agents in receiving signals from our body and mounting a specified immune response with targeted B cells and T cells against things like Lyme disease, as well as deploying long term memory immune cells and plasma cells which would give us long-term immunity to Lyme.
  • The Lyme and Tick-Borne Diseases Institute is focusing on investigating why mice get infected with Lyme, the infection persists, yet they never get sick from the infection.
  • If the team can identify human immune system deficits causing any of the above, they could identify immune therapies to overcome these shortcomings and treat all stages of Lyme disease.
  • Baumgarth and her team are also looking into the impact of tick-borne co-infections. They argue that it’s critical to study these diseases together rather than in isolation.

Autoimmune Responses and Lyme Disease

  • Professor Baumgarth suggests that Lyme disease may cause an autoimmune response, which can be particularly concerning for those with genetic predispositions to autoimmunity.
  • She cites several studies, both in the human model and mouse model, proving that Lyme disease creates an unnecessary increase in other antibodies from our immune system that aren’t Lyme-related, resulting in an autoimmunity phenomenon, increased inflammation, and potential immune system burnout.

Understanding Lyme Disease: A Veterinary Perspective

  • Professor Baumgarth’s veterinary background has allowed her to approach Lyme disease from a macro perspective. She emphasizes that Lyme, being a zoonotic disease, is fundamentally an infection that moves from animals to humans.
  • Lyme disease is often a natural infection in animals such as small rodents and birds, where ticks can bite them and transmit the disease.

Investigating the Human Immune Response to Lyme Disease

  • Our hosts discuss how humans’ immune responses to Lyme vary significantly. Some people are bitten by ticks multiple times without falling ill, while others suffer from chronic Lyme after just one bite.
  • This discrepancy might be due to factors such as genetic predispositions, environmental stresses, or an individual’s microbial load.

The Complexity of Eradicating Lyme

  • Eliminating Lyme is not as simple as wiping out a certain animal species, as the bacteria Borrelia can infect a variety of different rodents and even birds.
  • Borrelia is a complex bacterium that replicates slowly and requires a tick to infect a host. It’s constantly evolving and it’s not a simple task to eradicate Lyme from our ecology.

The Role of Antibiotics and Their Impact

  • Despite their potential long-term impact on our immune response, antibiotics are currently the most common form of treatment as soon as Lyme disease is diagnosed. Professor Baumgarth emphasizes a variety of risks when using antibiotics to treat Lyme disease.
  • While antibiotics can help in the short term, their effect on our long-term immunity to future infections is still unclear and Professor Baumgarth strongly warns against prolonged use of antibiotics.

Final Thoughts

  • Baumgarth is hopeful about the future of Lyme disease research. Despite the challenges and controversies, she believes that continued progress is possible with dedicated research and interdisciplinary collaboration.

Episode Wrap-up

  • Professor Nicole Baumgarth’s interview provides an enlightening look into the intricate world of Lyme disease and its complex interaction with our immune system. Her unique veterinary perspective coupled with her background in immunology, microbiology, and pathology as well as her research findings shed light on the challenges we face and offer hope for future breakthroughs in the fight against Lyme and tick-borne diseases.

__________________

**Comment**

My husband and I probably would not be on planet earth without long-term antibiotics so I’m glad this researcher didn’t treat us.  She’s just touting the safe narrative that is expected of academics working in research institutions that get their bread and butter from government grants with many strings attached, controlled by agencies that are completely corrupt.

Nobody denies the risk of prolonged use of antibiotics; however, Lyme/MSIDS can kill you in a myriad of ways.  This never seems to be discussed in the same sentence as prolonged antibiotics.  We would all love a safe, effective, affordable treatment.  Why aren’t researchers looking into this?  I’ll answer you: there’s no money in it, and it doesn’t fit with their narrative for a lucrative cash cow in a Lyme “vaccine.”  

It’s easy to be an arm-chair quarterback when it isn’t your neck on the chopping block.  All I can say is, whatever your opinions are about antibiotics before contracting Lyme/MSIDS, I guarantee they will change as you trod this pot-holed riddled, devastating path.  I hadn’t used antibiotics for 20 years before becoming infected.  I would use ANYTHING but antibiotics.  After I got infected I literally bathed in them for years.  I’m not proud of this, but they worked for both my husband and I, and many others.

It takes savvy to treat this complex illness and while anti-microbials are a MUST, there are many other important treatments required.  Please see the first link below for many treatments that experienced LLMDs have used with success.

For more:

Category:

Lyme, research, Treatment